Oncovista Innovative Therapies I (OVIT) 0.5500 $OVIT
Oncovista Retains Great Plains Capital as a Financial Advisor
Business Wire - Tue Jun 30, 8:00AM CDT
Oncovista Innovative Therapies, Inc. (OTCBB: OVIT) ("Oncovista" or the "Company"

is pleased to announce it has retained Great Plains Capital Partners, LLC ("GPCP" or "advisor"

as a financial advisor. GPCP, in a consultant capacity, will focus on strategic and corporate planning including assistance with mergers & acquisitions, and other strategic initiatives to ultimately help drive shareholder value for the investors of Oncovista. The Company recently settled a long-term litigation case that worked out to be very favorable, and plans to continue to advance and grow its pipeline.
Oncovista Settles 3 Year Litigation in New York Supreme Court
Business Wire - Thu Jun 18, 4:57PM CDT
Oncovista Innovative Therapies, Inc. (OTCBB: OVIT) ("Oncovista" or the "Company"

is pleased to announce its 3 year litigation has been settled favorably in the New York Supreme Court. The company is in the process of obtaining a short-term bridge loan that will propel its operations forward. Oncovista has two cancer fighting drugs, one in Phase I and one in Phase I/II, and it expects to continue the clinical trials in advancement accordingly. The company has multiple strategic plans in place that will drive shareholder value over the coming years and the settlement being reached now allows for those plans to materialize. CEO Alexander Weis commented on the outcome of the settlement, "I am glad that we have settled the case and we will move forward quickly with our best, most efficient targeted anticancer drugs." Mr. Weis will work with his advisors and clinical development team to continue to grow the company and he is pleased with the result of this long-term litigation.